9: Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma

9: Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma

Publication date: Jun 04, 2020

In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.

Concepts Keywords
Abdomen Stage tool
Adage Social media
Adjunctive Therapy Melanoma therapeutics
Adjuvant DNC disease
Adjuvant Therapy Metastatic disease
Adulation Melanoma
Agilent Respectable melanoma
Agonist Breast cancer
Agron Adamant therapy melanoma
Air Tumor
Aisle Micro metastases
Allah Minimal viable cancer
Antibody Advanced disease
Aspen Adamant disease
Asphalt D melanoma
Australia Receptive disease
Blockade Advanced cancer
Breast Teoh Melanoma
Breast Cancer C melanoma
Butte Surgery
Cancer Immunotherapy
Caviar Adjunctive therapy
Checkmate Chemotherapy
Chemotherapy Neoadjuvant therapy
Clinical Trial Health
Clinical Trials Medicine
CLR Cancer
Cohort Melanoma
Comparator RTT
Congress Adjuvant therapy
Control Arm 9
Cooperative Group Draft:Melissa Chase
Copal Primal therapy
Criminology Chemotherapy
Davar Alpha
Digital Adam
Dog CVD
Doublet Drug development
Drug Development
Embolism
Europe
Evolution
Force
Formulary
GDP
Geneva
Germany
God
Graph
Hematology
Hemorrhage
Hit Point
Hondo
Hospital
Humors
Immune Response
Immune System
Immunology
Immunotherapy
India
Interferon
Interferon Alpha
Iowa
Liberalism
Libya
Logical Inference
Long Distance Running
Lymph Node
Magnitude
Mark Smith
Melanoma
Metastases
Metastatic
Miami
Mono
Monotherapy
Mountain
Mylan
Mystic
Neal Adams
Neoadjuvant Therapy
Newton
Nib
Nile
Noma
Oncologist
Paradigm
PCR
Pembroke
Pennsylvania
Pickle
Pittsburgh
Placebo
Podcast
Principia
Punk
Regiment
Relapse
Relative Risk
Relax
Resection
RFs
Spear
Sting
Stomach
Swan
Targeted Therapies
Targeted Therapy
Tea
Teal
Thes
Toxicity
Tumor
United States
Vectra
Waas

Semantics

Type Source Name
disease MESH Melanoma
pathway KEGG Melanoma
drug DRUGBANK Medical air
drug DRUGBANK Natural alpha interferon

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *